Introduction
Antibodies are attractive tools for cancer immunotherapy due to their ability to bind tumor cells and to activate complement and/or to recruit effector cells through the interaction of their Fc regions with receptors for IgG (FcγR) or for IgA (FcαR). NK cells, monocytes and macrophages are able to kill tumor cells by antibody-dependent cell cytotoxicity following the engagement of CD16 or CD32, the low-affinity FcγRIII and FcγRII, or CD64, the high-affinity FcγRI. 1 In addition, the internalization of IgG containing immune-complexes bound to these receptors enhances antigen presentation to T cells. 2 NK cells and monocytes also produce a variety of cytokines upon FcγR engagement. 1, 3 Bispecific antibodies directed against mostly CD16 or CD64 and tumor-associated antigens have been therefore generated [4] [5] [6] and clinical trials in patients have been initiated. [7] [8] [9] However, the use of antibodies or bispecific antibodies in cancer therapy requires the generation of antitumor antibodies specific for a given tumor type. This has strongly limited the use of therapeutic antibodies in cancer patients over the last 20 years. Moreover, the injection of antibodies into the peripheral blood of patients hampers the efficiency of their targeting to tumor sites due to the nonspecific binding to FcγR + circulating cells and rapid catabolism. Circulating antibodies also provoke side-toxicity such as fevers, nausea, vomiting and leukopenia, likely due to the binding and activation of FcγR + cells. 7, 9 In addition to the toxicity, mouse antibodies induce human anti-mouse antibody (HAMA) 3 responses in patients, limiting their use for clinical purposes.
An alternative to the use of bispecific or tumor-specific antibodies is the recruitment of immune effector cells by the tumor itself. Tumor cells have been genetically engineered to enhance their immunogenicity. Tumor cells that express recombinant cytokines, 10, 11 MHC, 12 costimulatory molecules, 13, 14 or combinations of these molecules, 15 have been used to induce tumor regression in mouse models. However, the cells recruited in these cases are mostly limited to tumor-specific T cells or to a restricted subset of cells responsive to a given cytokine. An ideal strategy would be to recruit a large variety of cells from both the innate and the adaptative immunity that could exert a strong antitumor response through various mechanisms and which could be memorized.
An attempt to express single chain Fv (scFv) directed against FcγR by tumor cells is therefore attractive because of the broad expression of these molecules at the surface of cells playing a major role in the antitumor immunity. Here, we describe a new fusion molecule composed of one scFv directed against CD16 fused to the transmembrane region of platelet-derived growth factor receptor (PDGFR). When expressed at the surface of tumor cells, this molecule allows the recruitment and activation of NK cells, monocytes and IFN-γ-activated macrophages. It induces cytokine release, tumor cell cytotoxicity and overcomes the killer inhibitory eceptor (KIR)-mediated inhibition of NK cells. It increases also the tumor cell uptake by phagocytic cells. Finally, this fusion molecule prevents tumor cell growth in Winn tests performed with SCID mice.
Thus, this approach may have a broad use in triggering protective immunity against tumors or various pathogens as it could be also adapted using scFv directed against FcγrRI, or any component which binds to a Fc receptor.
Results

Cell surface expression of anti-CD16 scFv and binding of biotinylated sCD16
An anti-CD16 scFv was derived from the 3G8 mAb 16 and fused to the transmembrane domain of the PDGFR as described in Materials and methods. The expression of the anti-CD16 scFv fusion at the cell surface was first assessed by immunofluorescence with transiently transfected H1299 lung carcinoma tumor cells. Anti-CD16 scFv was detected at the cell surface of H1299 cells ( Figure  1a ), as observed for the anti-phOx scFv fusion (data not shown). H1299 clones stably transfected with either anti- CD16 scFv or anti-phOx scFv cDNAs were then isolated. Indirect immunofluorescence analyses performed with polyclonal rabbit IgG anti-scFv 17 ( Figure 1b) showed that cells from selected clones express scFv at their surface. Clone 25 (anti-CD16 scFv) and clone 57 (anti-phOx scFv) were used in all further studies.
Anti-CD16 scFv expressed at the cell surface of H1299 cells, or at least part of them, retain the ability of their soluble scFv counterparts to bind CD16. Biotinylated recombinant sCD16 corresponding to the two extracellular domains of the NA2 form of the CD16-B receptor 18 was incubated with H1299-anti-CD16 scFv cells. Its presence at the cell surface could be demonstrated by addition of FITC-streptavidin (Figure 1c, middle panel) . Furthermore, this binding could be inhibited by mixing the 3G8 anti-CD16 mAb with biotinylated sCD16 before incubation with the cells (Figure 1c, right panel) . No direct binding of FITC-streptavidin to H1299-anti-CD16 scFv was observed (Figure 1c, left panel) .
Cytokine production by CD16
+ cells stimulated with H1299-anti-CD16 scFv cells In a first set of experiments, the ability of Jurkat-CD16/γ cells 19 to produce IL-2 during a co-culture with H1299-anti-CD16 scFv cells for 24 h was examined. Co-cultures in presence of PMA (10 ng/ml) triggered IL-2 release as demonstrated by a specific quantitative ELISA (data not shown). The biological activity of the IL-2 produced during these co-cultures was demonstrated by a proliferation assay using the IL-2 dependent CTLL-2 cells (Figure 2a ). There was no significant IL-2 production with H1299-anti-phOx scFv cells co-cultured in similar conditions. As expected, no activation of Jurkat-CD16/γ cells was observed with PMA alone or with H1299-anti-CD16 scFv cells in absence of PMA (data not shown), since the triggering of IL-2 production by Jurkat cells requires two signals. 20 Similarly, the production of TNFα by freshly isolated human monocytes was induced when monocytes were co-cultured with H1299-anti-CD16 scFv cells, but not with H1299-anti-phOx scFv cells, as shown by the cytotoxicity induced by the corresponding co-culture supernatant on TNFα-sensitive L929 cells 21 ( Figure 2b ). No spontaneous TNFα production by freshly isolated monocytes was detected. Similarly, scFv-expressing H1299 cells did not produce TNFα when they were cultured alone or in the presence of sCD16.
H1299-anti-CD16 scFv tumor cells induce PBMC cytotoxicity
Whether the expression of anti-CD16 scFv at the surface of tumor cells could trigger antitumor cytotoxicity by freshly isolated huPBMC was then examined. H1299 lung carcinoma cells transfected with anti-CD16 scFv or antiphOx scFv encoding plasmids were mixed with huPBMC at different ratios and incubated at 37°C for 4 h before LDH measurement. HuPBMC killed H1299 cells only when these cells express anti-CD16 scFv. Figure 3a shows the cytotoxicity obtained with the huPBMC from one donor. 17.5% PBMC from this donor expressed CD16 + (data not shown). The cytotoxicity was inhibited by sCD16 in a dose-dependent manner (Figure 3b) .
A cytotoxicity ranging from 32 to 82% (mean value: 52.8% ± 14.1%; E:T = 100:1) could be achieved depending on the donor in five independent experiments. The killing was due to the binding of anti-CD16 scFv to CD16 expressed at the surface of huPBMC, as it was inhibited by the addition of 25 g/ml sCD16 (% inhibition mean value: 73% ± 20.6; E:T = 100:1; n = 4). In contrast, only 5.7% ± 6.4 cytotoxicity (E:T = 100:1; n = 5) were observed when huPBMC were mixed with H1299-anti-phOx scFv cells.
Enhanced phagocytosis of H1299-anti-CD16 scFv cells by macrophages
The phagocytosis of H1299-anti-CD16 scFv cells by IFNγ-activated macrophages 22 was then examined. First, the binding of IFNγ-activated macrophages to H1299-anti-CD16 scFv cells after 4 h of incubation at 4°C was analyzed. It was higher than the binding to H1299-anti-phOx scFv (11.5% versus 1.8%, respectively) (data not shown). At 37°C, IFNγ-activated macrophages bound and phagocytosed more H1299-anti-CD16 scFv cells (Figure 4a 
Figure 3 Cytotoxic activity of peripheral blood mononuclear cells (huPBMC) induced by H1299-anti-CD16 scFv cells. (a) Freshly isolated huPBMC were incubated for 4 h with H1299-anti-CD16 scFv cells (in the presence of sCD16 or not), or with H1299-anti-phOx scFv cells. Specific cytotoxicity was determined as described in Materials and methods. (b) Dose-dependent inhibition of cytotoxicity by sCD16 (E:T ratio: 50:1).
mAb or not (Figure 4b ). H1299-anti-phOx scFv cell extracts were used as control. A strong red fluorescence corresponding to phagocytosed PKH26-labeled H1299-anti-CD16 scFv cell extracts was observed within FITC- 
Winn test
The ability of H1299-anti-CD16 scFv tumor cells to recruit and activate CD16 + huPBMC in vivo was then tested in Winn tests. Anti-Asialo GM1-treated SCID mice were coengrafted with H1299 tumor cells expressing either anti-CD16 scFv or anti-phOx scFv and freshly isolated huPBMC (ratio 1:40). All the animals from the control group (H1299-anti-phOx scFv; n = 5) developed solid tumors (2/5) or tumor ascites (3/5) (Figure 5a ). These tumor cells still expressed anti-phOx scFv after growing in vivo (data not shown). In contrast, only one mouse (1/6) engrafted with H1299-anti-CD16 scFv developed a solid tumor (Figure 5a ). Cells isolated from this tumor still expressed anti-CD16 scFv. Thus, co-engraftment of tumor cells expressing anti-CD16 scFv and huPBMC results in a strong inhibition of tumor development in SCID mice. H1299-anti-CD16 scFv and H1299-anti-phOx scFv cells exhibited the same growth kinetics in absence of huPBMC (data not shown). In addition, all mice injected with H1299-anti-CD16 scFv cells were alive after 92 days, while only two of five control mice were alive at that time (Figure 5b ).
Figure 4 Phagocytosis of H1299-anti-CD16 scFv cells by IFNγ-activated human macrophages. (a) PKH26-labeled tumor cells (H1299-anti-CD16 scFv or H1299-anti-phOx scFv cells) were incubated with IFNγ-activated macrophages for 4 h at 37°C (E:T ratio: 1:1). Macrophages were then stained with FITC-CD14/CD64 mAbs and 10 000 cells were analyzed using a FACScalibur. Double-labeled cells (upper right quadrants) correspond to IFN␥-activated macrophages stained with FITC-CD14
Discussion
In this report, a novel antibody-based strategy allowing the recruitment and activation of immune effector cells is described ( Figure 6 ). It is based on the expression of anti-FcγR scFv at the tumor cell surface. It allows FcγR-dependent cell functions to be triggered and tumor cell cytotoxicity to be induced without requiring the isolation and use of specific antitumor antibodies. This represents an important benefit since many tumors do not express specific tumor antigens. We showed that a functional scFv directed against FcγRIII (CD16) can be expressed at the surface of human tumor cells and can activate It should be noted that a murine tumor model using immunocompetent mice is difficult to develop as the anti-mouse FcγR mAb which is available, 2.4G2, is directed both against FcγRII and FcγRIII, and does not discriminate between ITIM and ITAM bearing receptors. 1 The targeting of FcγR or FcαR by a specific ligand expressed on tumor cells has multiple advantages compared with the surface expression of other proteins such as CD3 23 or co-stimulatory molecules. [13] [14] [15] In contrast to these molecules, FcR are widely expressed on a large variety of cells of the immune system ( Figure 6 ) and their engagement provokes the activation of multiple cell functions. 1, 24 Interestingly, cells from both innate and adaptative immunity can be recruited and activated by the binding to and triggering of FcR. 1 On the one hand, potent FcγR + killer cells such as G-CSF-activated neutrophils or NK cells can be recruited to directly kill tumor cells through the activation of FcγRI or FcγRIII, respectively. 4, 25 On the other hand, the enhancement of phagocytosis of tumor cells or cell extracts by antigenpresenting cells through FcγR could induce a protective long-term immunity to tumors by allowing recruitment of T cells. [26] [27] [28] The expression of anti-CD16 scFv at the tumor cell surface allowed demonstration of the fact that CD16 expressed on activated human macrophages is involved in phagocytosis. Of note is that the present approach provides a distinct advantage in that no particular tumor antigen needs to be known for antigenpresenting cell targeting. Another advantage in using the present approach is the absence of co-recruitment of 
(a) Percentage of animals without tumor in the control group (H1299-anti-phOx scFv cells) (open circles), or in the group of mice engrafted with H1299-anti-CD16 scFv cells (black squares). (b) Percentage of survival in the control group (H1299-anti-phOx scFv cells) (open circles), or in the group of mice engrafted with H1299-anti-CD16 scFv cells (black squares).
FcγRII and FcγRIII expressed on neutrophils, which induces a severe toxicity. 29 Our data also show that it is possible to block the negative immuno-modulatory function exerted by KIR on NK cells by expressing anti-CD16 antibodies on HLA + tumor cells otherwise resistant or poorly sensitive to NK cell activity. The balance between the positive signal triggered by the engagement of FcγRIII-A on NK cells and the negative signal due to the KIR/HLA interaction can therefore be modified in favor of the former one by expressing anti-FcγR scFv at the tumor surface. It clearly demonstrates the existence of fine tuning between the activation and inhibition pathways in these cells. 30 The ability to trigger the killing of HLA class I + tumor cells may be useful, since it has been postulated that KIR expression may result in the inability to control tumor growth by killer cells. 31 
Gene Therapy
Figure 6 Diagram representing the targeted immunotherapy (the 'Hooking tumor strategy') based on the expression of recombinant antibody fragments directed against FcγR on tumor cells. Cells from both innate and adaptative immunity can be recruited and activated by the triggering of Fc␥R. Fc␥R+ killer cells, such as G-CSF-activated polymorphonuclear cells (PMN) or NK cells, can be recruited to kill tumor cells through the activation of FcγR. The enhancement of phagocytosis of tumor cells or cell extracts by antigen-presenting cells such as macrophages or immature dendritic cells (DC) through Fc␥R could also induce a protective longterm immunity to tumors by allowing recruitment of specific T cells. The engagement of Fc␥R also triggers the production of various cytokines and pro-inflammatory molecules involved in antitumor activities.
This antibody-based therapy strategy for cancer treatment also has several potential advantages over the use of engineered bispecific antibodies directed against FcγR and tumor antigens. [32] [33] [34] First, as already discussed, no tumor-specific antibody has to be isolated and the molecule can be used for the treatment of different tumor types that do not express known tumor-associated antigens. Second, the recruitment of effector cells should be improved by using an intra-tumoral gene delivery system, which allows the expression of the anti-FcγR scFv in situ. No systemic delivery is needed, avoiding the rapid trapping and clearance of the injected antibody by FcγR + cells present in the circulating blood, liver and other organs. In addition, it should decrease the appearance of the side-effects provoked by the activation of circulating FcγR + cells upon binding of IgG antitumor antibodies or bispecific antibodies directed against FcγR and tumor antigens. Third, it is likely to be weakly immunogenic, since no constant domain of murine immunoglobulin is present in the recombinant antibody fragment. A weak immunogenicity may even have some benefits, by triggering an adjuvant immune effect against tumor cells expressing the transgene. In the case of an HAMA immune response that could block the interaction of surface scFv and immune cells, an alternative would be to use human anti-FcγR scFv. However, it should be pointed out that our approach, as other cancer gene therapy approaches, relies on the use of an efficient gene delivery system, allowing repeated injections into the tumor. Although one can expect that the recruitment of even a limited number of FcγR + cells from various hematopoietic lineages can be sufficient to trigger a potent antitumor immune response, it has still to be documented.
In conclusion, our data demonstrate that anti- 
Materials and methods
Construction of anti-CD16 surface display vector
The anti-CD16 scFv cDNA was derived from the 3G8 mouse mAb 16 by a three-step PCR method as previously described. 35 It was then cloned into the eukaryotic expression Neo R pHook-2 vector (kind gift of Dr M Russel, Invitrogen, San Diego, CA, USA), using the SfiI and NotI restriction sites. The pHook-2 vector initially contains a cDNA insert encoding for an anti-4-ethoxy-methylene-2-phenyl-2-oxazolin-5-one scFv (anti-phOx scFv) fused to a mouse PDGFR transmembrane domain through a repeated c-myc motif, under the control of a RSV promoter. 36 The cDNA encoding anti-phOx scFv was removed and replaced by the anti-CD16 scFv cDNA after deletion of an extra-3Ј NotI site by site-directed PCR mutagenesis. The anti-phOx scFv construct was used as negative control in all further experiments.
Cell lines and transfections
The non-small cell lung carcinoma H1299 adherent cells (kind gift of Dr L Bracco, Aventis, Vitry sur Seine, France), were cultured with DMEM (Seromed, Berlin, Germany), 10% heat-inactivated fetal calf serum (FCS) (Hyclone, Logan, UT, USA), 2 mm l-glutamine (Seromed), 1 mm sodium pyruvate (Seromed), 100 IU/ml penicillin (Seromed) and 100 g/ml streptomycin (Seromed) (culture medium). 5 × 10 6 cells were transformed with 1 g of plasmid encoding anti-CD16 scFv or anti-phOx scFv. Transfections were performed using lipofectAMINE (Gibco-BRL, Paisley, UK) according to the manufacturer's instructions. Briefly, 1 g of plasmid DNA was mixed with 5 g of lipofectAMINE in 500 l Opti-MEM medium (Gibco-BRL) and incubated for 30 min at room temperature (RT) before being added to H1299 cells. Cells were then incubated for 4 h at 37°C. After removing Opti-MEM, 3 ml of fresh culture medium was added. Stable transformants were selected by adding G418 (Geneticin; Gibco-BRL) (2 mg/ml) 48 h later and examined for scFv cell surface expression. They were further cloned and grown in the presence of 1 mg/ml G418.
Jurkat-CD16/γ transfected cells 19 were grown in culture medium containing 0.4 mg/ml G418. CTLL-2 cells (kind gift of Dr RS Lee, Institut Curie, Paris, France), were grown in 1640 RPMI medium (Seromed) supplemented with 10% FCS, 2 mm l-glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, 10 m β-2 mercapto-ethanol (Gibco-BRL) and 100 IU/ml recombinant human IL-2 (huIL-2) (Chiron, Emeryville, CA, USA).
Mouse fibroblast L929 cells 21 were kindly provided by Dr E Tartour (Hô pital Européen Georges Pompidou, Paris, France). They were grown in 1640 RPMI supplemented with 10% FCS, 2 mm l-glutamine, 1 mm sodium pyruvate, 100 IU/ml penicillin and 100 g/ml streptomycin.
IFNγ-activated macrophages were obtained as previously described. 22 Immunofluorescence assays H1299 cells were grown in two-well-Labtek chamber slides (Nunc, Roskilde, Denmark) (2 × 10 5 cell/well) for 24 h and transfected with 250 ng of plasmid encoding anti-CD16 scFv or anti-phOx scFv, or mock transfected. Indirect immunofluorescence assays were performed 24 h after transfection. After two washes in PBS with calcium and magnesium (PBS-Ca Stable transfected cells were examined for scFv surface expression using indirect immunofluorescence assays. 5 × 10 5 transformed cells were washed twice with PBS and incubated for 30 min at 4°C with rabbit IgG anti-scFv diluted in PBS (2 g/ml). After two washes in PBS, scFv were revealed with FITC-labeled goat Ig anti-rabbit IgG. Cells were then washed in PBS and fixed with 500 l of PBS-1% formaldehyde. Ten thousand cells per experiment were analyzed with a FACScalibur cytometer (Becton Dickinson, San Jose, CA, USA) using the Cellquest program.
Biotinylated recombinant soluble CD16 binding
Purified recombinant soluble CD16 (sCD16), 37 kindly provided by Pr C Sautès-Fridman, was biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA), according to the manufacturer's instructions, with a 25 biotin/sCD16 molar ratio. The presence of the 3G8 epitope on biotinylated sCD16 was assessed with a sandwich ELISA using the 3G8 mAb as capture antibody. The binding of biotinylated CD16 at the cell surface was detected by a direct fluorescence assay using FITC-streptavidin (Jackson Immunoresearch) as the revealing reagent. Inhibition experiments were performed by mixing biotinylated sCD16 with purified 3G8 mAb (4:1 molar ratio) for 30 min at 4°C before addition to the cells.
IL-2 production assay 10
5 Jurkat-CD16/γ transfected cells 19 were stimulated for 24 h with 2 × 10 5 H1299-anti-CD16 scFv or H1299-antiphOx scFv cells, in the presence of 10 ng/ml PMA (Sigma, St Louis, MO, USA). Culture plates were then centrifuged (800 g, RT, 5 min) and supernatants harvested. The presence of huIL-2 was measured by ELISA with the Quantikine human IL-2 kit (R&D, Oxford, UK). The IL-2 bioactivity was evaluated with the IL-2-dependent mouse T cell line CTLL-2. Cells were cultured in the presence of 10 IU/ml huIL-2 for 48 h. After three washes in RPMI 1640 medium, 2 × 10 4 CTLL-2 cells were cultured for 48 h in the presence of serial dilutions of co-culture supernatants or of recombinant huIL-2 (from 5 × 10 -5 to 50 IU). Cell proliferation was measured by the CellTiter 96 Aqueous Non-Radioactive Proliferation Assay (Promega, Madison, WI, USA).
Monocyte activation
HuPBMC from healthy donors were isolated from cytapheresis rings (obtained from the Etablissement de Transfusion Sanguine, Hô pital de l'Hô tel-Dieu, Paris, France) by density gradient centrifugation (Lymphocyte Separation Medium, d: 1.077, Roche Diagnostics, Meylan, France). Monocytes were isolated by plastic adherence by incubating 10 5 huPBMC in 100 l RPMI 1640 culture medium/well of a 96-well microplate at 37°C for 3 h. Monocytes were then co-cultured with 5 × 10 4 H1299-anti-CD16 scFv or H1299-anti-phOx scFv cells at 37°C for 15 h. The presence of TNFα in culture supernatants was measured by a cytotoxicity assay with the L929 cell line. 21 2 × 10 4 L929 cells/well were grown overnight in 96 wellmicroplates in triplicates. Co-culture supernatants or recombinant TNFα (from 0.1 ng to 37.5 fg) and 2 g/ml actinomycin D (Sigma) were then added for a further 20 h culture period. The proliferation of L929 cells was measured by adding 100 g/well of MTT (Sigma) (4 h, 37°C, in the dark) and then 100 l/well of 20% SDS-50% N,Ndimethyl formamide (DMF), pH 4.7 (Sigma) (20 h, 37°C, in the dark). The percentage of cytotoxicity was calculated according to the following formula: cytotoxicity (%) = 1 Ϫ (OD 550 nm experiment/OD 550 nm control) × 100.
Cytotoxicity assay
HuPBMC cytotoxicity was determined in a 4 h lactate dehydrogenase (LDH) release cytotoxicity assay in triplicate, using H1299-anti-CD16 scFv or H1299-anti-phOx scFv cells as target cells. The specific cytotoxicity was calculated according to the following formula: specific lysis (%) = (experimental -effector spontaneous -target spontaneous) x 100/target maximun -target spontaneous.
H1299-anti-CD16 scFv cells were pre-incubated with different doses of sCD16 for 20 min at RT before adding huPBMC in inhibition experiments.
Tumor binding to and phagocytosis by IFNγ-activated macrophages
A two-color immunofluorescence assay was used to determine the binding and phagocytosis of H1299-anti-CD16 scFv or H1299-anti-phOx scFv cells by IFNγ-activated macrophages. Tumor cells were labeled with PKH26 dye (Sigma) according to the manufacturer's instructions and cultured overnight to eliminate excess dye. 3 × 10 5 macrophages (100 l of RPMI 1640 culture medium) were distributed in polypropylene round-bottom capped tubes (Becton Dickinson). 100 l of 3 × 10 5 labeled cell targets were then added to the tubes. The cell mixture was incubated at 4°C or 37°C for 4 h. Macrophages were then stained with FITC-CD14/CD64 mAbs (Beckman Coulter, Brea, CA, USA).
Fluorescence cell analysis for double staining was performed using a FACSCalibur (Becton Dickinson). FITC-CD14
+
/CD64
+ macrophages also exhibiting red fluorescence were considered as phagocytic cells or tumor cell/macrophage doublets. Percentage of phagocytosis was calculated using the following formula: 38, 39 
PKH26
+ cells (4°C).
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Epifluorescence microscopy was performed by culturing 5 × 10 5 macrophages in two-chamber culture Labtek slides (Nunc) for 16 h. Non-adherent cells were removed and macrophages were washed twice with PBSCa
++
Mg
++ . Macrophages were then incubated on ice for 30 min with PBS containing anti-CD16 3G8 mAb (25 g/ml) or not. PKH26-labeled H1299-anti-CD16 scFv or H1299-anti-phOx scFv cells were washed with PBSCa
++
Mg
++ , sonicated (20 000 Hz, 130 W, 10 s, three times), added to macrophages at an E:T ratio of 1:1 and incubated for 4 h at 37°C in a 5% CO 2 humidified atmosphere. Cells were then washed twice with PBS-Ca
++
Mg
++ , fixed with PBS-Ca ++ Mg ++ -4% formaldehyde, and stained with FITC-CD14/CD64 mAbs (Beckman Coulter). Nuclei were stained with Vectashield containing DAPI (Vector) and analyzed under an epifluorescence microscope.
Animals
Eight-week-old female SCID mice (C.B-17 1cr scid/scid), obtained from IFFA Credo (L'Arbresle, France) were maintained under pathogen-free conditions in microisolation cages. Serum Ig levels were quantitated by enzyme-linked immunosorbent assay (ELISA). 40 Animals with antibody titers exceeding 1 g/ml were excluded from the experiments. To eradicate residual NK cells, 25 l of an anti-Asialo GM1 antibody solution (WakoOsaka, Japan) were administered intraperitoneally 1 day before tumor-cell grafting and every 5 days up to 25 days after tumor cell injection.
Winn assay H1299-anti-CD16 scFv and H1299-anti-phOx scFv cells were first adapted for growth in vivo in SCID mice. Cells were then isolated from subcutaneous tumors and frozen. They were thawed before each experiment, cultured in vitro for 72 h and analyzed for scFv surface expression before engraftment. Groups of six mice were subcutaneously injected in the left flank with a mixture of 1.5 × 10 6 transfected H1299-scFv cells and 50 × 10 6 huPBMC resuspended in 200 l PBS. Tumors were measured using a caliper. The longest dimension (a) and perpendicular width (b) were determined, and tumor volume (v) was calculated according to the formula: v = ab 2 /2. Mouse survival was monitored for 92 days.
